Summary
This translational research demonstrates that circulating tumour DNA exhibits enriched representation in fragment sizes between 90–150 bp, a property exploitable for improved cancer detection. By applying in vitro and computational size-selection methods, the authors achieved >twofold median enrichment in ctDNA detection in >95% of cases and >fourfold enrichment in >10% of cases. Integration of fragment length analysis with copy number profiling substantially improved cancer classification performance (AUC >0.99 for advanced cancer; AUC >0.91 for specific cancer types), suggesting fragment size analysis could complement or substitute for deeper sequencing strategies in cell-free DNA analysis.
Regional applicability
The findings are applicable to UK cancer diagnostics and precision oncology development, particularly for non-invasive early detection strategies in the NHS. Implementation would require integration into existing ctDNA sequencing workflows and validation within UK patient populations across diverse cancer types.
Key measures
ctDNA fragment size distribution (bp); median enrichment fold-change in detection; area under curve (AUC) for cancer identification; frequency of clinically actionable mutations detected; sensitivity and specificity by cancer type
Outcomes reported
The study measured circulating tumour DNA (ctDNA) fragment size distributions across 344 plasma samples from 200 cancer patients and assessed detection sensitivity improvements through fragment size selection. Key outcomes included enrichment of ctDNA detection, identification of clinically actionable mutations, and improved cancer classification accuracy using fragment length analysis.
Topic tags
Dig deeper with Pulse AI.
Pulse AI has read the whole catalogue. Ask about this record, its theme, or how the findings apply to UK farming and policy — every answer cites the underlying studies.